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Abstract
Summary We have developed a short, patient-reported out-
come questionnaire—the Osteoporosis Assessment Question-
naire—Physical Function (OPAQ-PF)—that assesses the im-
pact of osteoporosis on physical function. OPAQ-PF contains
15 items in three domains (mobility, physical positions, and
transfers) and has content validity in osteoporosis patients with
and without a history of fracture.
Introduction This paper describes the development of the
Osteoporosis Assessment Questionnaire—Physical Function
(OPAQ-PF), a patient-reported outcome (PRO) questionnaire
based on OPAQ v.2.0 (60 items, 14 domains) that assesses the
impact of osteoporosis on physical function.
Methods OPAQ v.2.0 was administered to patients with oste-
oporosis. Item response theory methodology and clinical judg-
ment were used to retain/eliminate items. The resulting instru-
ment was modified during two sets of concept elicitation and
cognitive debriefing interviews with osteoporosis patients.
Results Item response theory-based analysis of OPAQ v.2.0
(n=1,478) coupled with clinician input resulted in the
generation of a 21-item, six-domain instrument with a fre-
quency response format. Interview data from 32 participants
were used to modify this version and led to generation of the
final instrument, OPAQ-PF. This final version has a severity
response format and contains 15 items in three domains (mo-
bility, physical positions, and transfers) that group together to
provide an overall assessment of physical function in patients
with osteoporosis. Twenty-two of the 32 interview partici-
pants (69 %) had previously sustained a fracture. Symptoms
occurred primarily in these patients.
Conclusions OPAQ-PF represents a brief, focused, PRO in-
strument that assesses physical function in patients with osteo-
porosis, specifically related to mobility, physical positions, and
transfers. This questionnaire has content validity in osteoporo-
sis patients who have, and have not, sustained a prior fracture.
Keywords Fracture . Lowbonemass density . Osteoporosis .
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Introduction
Osteoporosis is a systemic skeletal disease characterized by
micro-architectural deterioration of bone with resultant low
bone mass, bone fragility, and increased fracture risk [1].
Osteoporosis-related fractures, which most commonly occur
at the hip, spine, and wrist, may be followed by full recovery
or by chronic pain, disability, and death [1].
Osteoporosis is most prevalent in middle-aged and elderly
adults, and currently affects approximately 10 million individ-
uals in the USA [2]. It is estimated that up to 50 % of women
and 25 % of men over the age of 50 years will experience an
osteoporotic fracture in their remaining lifetime [2].
The effects of osteoporotic fracture on morbidity and mor-
tality are significant. In a retrospective US Medicare claims
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database analysis of over 97,000 patients with vertebral com-
pression fractures, the hazard ratio for mortality vs. control
patients was 1.83 (95 % confidence interval [CI], 1.80–1.86)
[3]. Similarly, the prospective US Study of Osteoporotic Frac-
tures found that, compared with women without vertebral
fracture, women with ≥1 vertebral fracture had a 1.23-fold
greater age-adjusted mortality rate (95 % CI, 1.10–1.37) [4].
Mortality increased with the number of vertebral fractures,
rising from 19 per 1,000 woman-years in those without frac-
tures to 44 per 1,000 woman-years in those with ≥5 fractures
(p for trend <0.001).
Osteoporotic fracture-associated morbidity may impact on
patients in several ways, including impaired physical func-
tioning, disability, depression, social isolation, pain, loss of
independence, and decreased quality of life [5–7]. Many such
consequences can be measured using an appropriate specific
patient-reported outcome (PRO) instrument.
The Osteoporosis Assessment Questionnaire (OPAQ) ver-
sions 1.0, 2.0, and short version are validated, reliable PRO
measures used extensively in clinical trials to assess patient
outcomes in individuals with osteoporosis [8–14]. The instru-
ments were developed as disease-targeted questionnaires that
would discriminate between postmenopausal women with and
without osteoporotic fracture [11], and were also intended to
be used as evaluative instruments in clinical trials [11].
The OPAQ v.1.0 contained 84 questions in 18 domains and
four dimensions (physical function, emotional status, symp-
toms, and social interactions), plus 18 questions measuring
satisfaction with each of the domains [11]. In 2000, Silverman
modified the OPAQ and created v.2.0, a 14-domain, 60-item
questionnaire that retained the same four dimensions as v.1.0
[11]. Our aim was to create a short, osteoporosis-targeted
instrument, based on OPAQ v.2.0 and known as OPAQ—
Physical Function (OPAQ-PF), which could be used in clini-
cal trials to evaluate the impact of new osteoporosis treatments
on patients’ outcomes. Initially, we sought to develop a mea-
sure of the impact of osteoporosis on the dimensions of
physical functioning, fear of falling, independence, and symp-
toms. However, this objective was re-evaluated and modified
based on the interim results, and the instrument was refocused
on physical function only. This paper describes the develop-
ment of OPAQ-PF.
Methods
The study was conducted in two phases.
Phase 1: item elimination
Phase 1 consisted of a post hoc analysis of data generated
when the 60-item OPAQ v.2.0 was administered, at the study
baseline visit, to 1,478 patients enrolled in the Multiple
Outcomes of Raloxifene Evaluation (MORE) trial [15]. This
phase 3, multicenter, double-blind, placebo-controlled, ran-
domized clinical trial enrolled ambulatory, postmenopausal
women aged ≤80 years with a diagnosis of osteoporosis
(defined as the presence of vertebral fractures or a femoral
neck or vertebral spine T-score of ≤−2.5) [15].
Each of the 60 items was analyzed using item response
theory (IRT) methodology. First, exploratory factor analysis
was used to confirm unidimensionality of each of the 14
domains independently. For each domain, a scree plot was
used to determine whether only one construct was being
measured in MORE clinical trial population.
Next, two sets of graphs (item characteristic curves [ICCs]
and item information curves [IICs]) were generated to dem-
onstrate how well items reflected the concept being measured,
to provide graphical representations of the floor and ceiling
effects of patient responses to each item, and to act as a focus
for discussing the clinical relevance of the measured concepts
(data not shown). The ICCs were used to assess each item’s
ability to discriminate across the continuum of the underlying
construct experienced by patients. The extent to which each
item was related to the underlying construct, and the range
over which the item could distinguish responses, were deter-
mined using the IICs. Analyses were conducted using Mplus
(Muthén and Muthén, Los Angeles, CA, USA) statistical
software. More information on IRT methodology can be
found in the article by Edelen and Reeve [16].
Items and responses were modified or subdivided, if nec-
essary, and new items and responses could be added. Criteria
for retaining items included: good IRT item performance
(based on visual assessment of ICCs and IICs); good discrim-
ination within a wide range of the construct; clinical relevance
as assessed by two of the authors (SS, DTG); and construct
relevance. The aim of this study phase was to identify items
that performed well according to IRT criteria, and to use IRT
results as a major factor in reducing the initial set of 60 items
to onemore closely focused on physical function (a dimension
including mobility, physical positions, and transfers), fear of
falling, independence, and symptoms, and amenable to qual-
itative investigation based on concept elicitation and cognitive
debriefing interviews with osteoporosis patients.
Phase 2: qualitative research
Phase 2 comprised a cross-sectional, iterative, qualitative in-
vestigation to determine the impact of osteoporosis on pa-
tients’ lives, to evaluate the suitability of the interim version of
OPAQ generated in phase 1 as an endpoint in clinical trials,
and to clarify the conceptual focus of the final instrument. This
involved conducting concept elicitation and cognitive
debriefing interviews on the interim version of the OPAQ.
Interviews were conducted in 2010 and 2011 according to a
semi-structured guide. This study phase was conducted in two
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discrete stages (‘first stage’ and ‘second stage’), each with a
separate recruitment process. Substantial modifications were
made to the instrument between these stages so that it focused
solely on physical function in the second stage.
Interviews were audio-recorded and transcribed to facilitate
data analysis. Methodology and analyses were in line with the
US Food and Drug Administration (FDA)’s guidance on PRO
instrument development and modification, and recent Interna-
tional Society for Pharmacoeconomics and Outcomes Re-
search (ISPOR) recommendations [17–19]. Demographic
and interview data are reported separately for the two stages
of this phase.
Study population
Participants were recruited through three clinical sites in the
USA. Full Institutional Review Board (IRB) approval was
obtained from the Western IRB, Olympia, Washington, USA
(first stage), and the Independent IRB, Plantation, Florida,
USA (second stage), prior to patient recruitment.
Inclusion criteria were: female gender, ≥50 years of age,
ambulatory (able to walk with or without assistance), and
diagnosis of osteoporosis at least 1 year previously. The final
study population included patients with osteoporosis of dif-
fering degrees of severity (who were therefore at different
levels of fracture risk), and patients who had, and had not,
experienced an osteoporosis-related fracture. Patients were
allocated by a clinician to one of three diversity groups,
according to the following inclusion criteria:
& Diversity group 1: (T-score between −1.0 and −2.5 at the
femoral neck or spine and 10-year probability of hip
fracture ≥3 %) or 10-year probability of major
osteoporosis-related fracture ≥20 %.
& Fracture probabilities were based on the World Health
Organization’s ‘FRAX®’ algorithm, which estimates 10-
year probabilities of hip fracture and major osteoporotic
fracture (defined as clinical vertebral, hip, forearm, or
proximal humerus fracture) based on the patient’s femoral
neck bone mineral density and clinical risk factors [1].
& Diversity group 2: T-score≤−2.5 and fragility fracture of
the usual osteoporosis fracture sites (e.g., spine, wrist, hip,
rib, or pelvis) in the past 12 months, as determined by the
attending physician.
& Diversity group 3: T-score≤−2.5 and fragility fracture of
the usual osteoporosis fracture sites (e.g., spine, wrist, hip,
rib, or pelvis) >12 months previously.
The study protocol mandated the exclusion of patients with
comorbid conditions that would affect their ability to differ-
entiate any symptoms and impacts of osteoporosis from
symptoms/impacts of other conditions. No patient participated
in both stages.
Demographic and medical history data were provided on
structured forms completed by the patient or clinical site staff
and were summarized using descriptive statistics.
Interviews: concept elicitation
Interviews commenced after patients had provided written
informed consent. Semi-structured, qualitative, one-on-one
concept elicitation interviews involved the interviewer ask-
ing each participant questions about osteoporosis-related
symptoms and impacts that were important to them. Pa-
tients were excluded from the analysis if they were unable
to differentiate between osteoporosis and comorbid condi-
tions as the cause of symptoms or impacts throughout the
discussion. Patients who could discuss symptoms/impacts
of osteoporosis specifically at some point in the interview
were retained in the full analysis, but any symptoms/
impacts that they had difficulty in attributing specifically
to osteoporosis were excluded. Issues related to OPAQ
dimensions/domains of interest gathered during these inter-
views provided evidence for content validity of the new
instrument.
The resulting data were analyzed using a thematic analysis
approach [20]. This involved reading and re-reading the data
to identify themes and categories that centered on particular
phrases, incidents, and types of behavior, in line with concepts
and themes outlined in the interview guide. The codes used
were captured in a codebook and in an evidence-based coding
frame that were continuously updated as new categories and
codes emerged. As each interview transcript was analyzed, the
number of new codes generated by that transcript was
recorded and used to determine saturation (the point at which
no new categories, concepts, dimensions, or incidents
emerged during the theory development process) [21]. Qual-
itative data analysis was assisted by using ATLAS.ti software
version 5.7.1 (Cleverbridge, Chicago, IL, USA).
Interviews: cognitive debriefing
Following concept elicitation, participants were asked to com-
plete the interim version of the OPAQ. The interviewer then
asked participants for their thoughts and opinions on the
general design of the instrument, item semantics, applicability
and interpretation, response options, and recall period. Anal-
ysis of cognitive debriefing interviews was conducted on an
overall questionnaire basis and on an item-by-item basis [22],
with the goal of evaluating and improving the instrument’s
content validity. This included identifying items that presented
cognitive challenges.
The questionnaire remained open to modification through-
out the debriefing process. New items were added, redundant
items removed, and minor changes made to the introduction,
item wording, response options, and layout.
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Results
Phase 1
Unidimensionality was confirmed for each domain of the
OPAQ v.2.0. Information generated by the ICCs and IICs
(available from the corresponding author) was used in con-
junction with expert opinion (SS and DTG are both globally
renowned key thought leaders on quality of life issues and
measurement in osteoporosis) to make decisions regarding
item deletion, retention, modification, or subdivision (e.g.,
“How often did you have trouble either walking one block
or climbing one flight of stairs?” was divided into two ques-
tions: “How often did you have trouble walking one block?”
and “How often did you have trouble climbing stairs or
steps?”). Items were included in the interim version of OPAQ
only if deemed relevant to the overall concepts of physical
function, fear of falling, independence, and symptoms that
were the original intended focus of the final questionnaire.
The primary reason for item retention was good endorsement
of the concept by IRT curves. However, some items that
measured a clinically important aspect of the underlying con-
struct were retained based on expert opinion, even if their
ICCs and IICs did not show well-distributed responses. Slight
modifications to the wording of items and responses were
based solely on expert opinion.
The resulting interim version of OPAQ contained 21 items
in six domains: walking and bending (six items); sitting and
standing (three items); transfers (four items); back ache and
pain (two items); fear of falling (three items); and indepen-
dence (three items). Slight modifications to item wording and
response option content (e.g., ‘very often’ changed to ‘often’,
and ‘almost never’ changed to ‘seldom’) were necessary to
focus concepts on domains of interest, to improve clinical
relevance, and to describe concepts as depicted by patients
per expert opinion. Resulting response formats were: ‘all
days’, ‘most days’, ‘some days’, ‘few days’, ‘no days’ for
15 questions, and ‘always’, ‘often’, ‘sometimes’, ‘seldom’,
‘never’ for the remaining six questions.
Phase 2
This phase involved analysis of concept elicitation and cog-
nitive debriefing data from 32 patients (first stage, 14 patients;
second stage, 18 patients). All patients were receiving at least
one prescription or non-prescription treatment for osteoporo-
sis. Non-prescription treatments included calcium and vitamin
D supplements.
First stage: patient demographics
Twenty-one patients (eight in diversity group 1, five in group 2,
and eight in group 3) were recruited for the first stage of phase
2. However, data from seven of these participants were exclud-
ed from the analysis because of poor mastery of English (n=1)
or because they were unable to distinguish the symptoms and
impacts of osteoporosis from those of other comorbid condi-
tions (n=6). These seven patients were white, with a mean
(±standard deviation [SD]) age of 77.1±10.2 years and a mean
disease duration of 9.7±7.9 years.
Demographic data for the 14 remaining patients (seven in
diversity group 1, four in group 2, three in group 3) are shown
in Table 1. This cohort was predominantly white (86 %) and
had a mean (±SD) age of 68.0±11.3 years and a mean disease
duration of 5.9±5.3 years. Seven patients were recruited at each
of the two clinical sites. In total, 14 fractures had been sustained
by ten of the 14 patients. Five of these fractures affected the
spine. Remaining fractures were distributed among hip (n=2),
wrist (n=1), shoulder (n=1), ribs (n=2), femur (n=1), and
foot/toe (n=2). It proved impossible to recruit patients who
were free of comorbid conditions that might be associated with
fatigue, poor sleep, pain, or limited mobility, and comorbid
conditions affecting these patients included Parkinson’s dis-
ease, polymyalgia rheumatica, breast cancer, hyperlipidemia,
osteoarthritis, rheumatoid arthritis, and diabetes.
First stage: concept elicitation
In this part of the interview, participants were asked about: (1)
impacts osteoporosis had on their lives; (2) activities they
were able/unable to do or avoided; and (3) any symptoms of
which they were aware. The interviews therefore had a
broader focus than the content of the instrument administered
at that stage. We report here only the findings of relevance to
the content of the final version of OPAQ-PF.
Relevant concept elicitation data from the first stage inter-
views are presented in conjunction with concept elicitation
data from the second stage interviews in Table 2, and described
in the section titled “Second stage: concept elicitation”. In the
first stage of phase 2, no new codes were added after the 12th
concept elicitation interview, demonstrating that data satura-
tion was achieved.
First stage: cognitive debriefing
Cognitive debriefing data showed that the interim version of
OPAQ was well received but that a number of modifications
were required. These included: (1) moving from a frequency
response format to a severity response format; (2) making the
introductionmore informative and less likely to be overlooked;
(3) adding a stem to the questionnaire to ensure participants
responded specifically according to their osteoporosis and not
another comorbid condition; (4) removing groups of items that
did not yield information regarding the impact of osteoporosis
on physical function; (5) improving item wording; (6)
subdividing items that asked about more than one issue (e.g.,
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bending, lifting, and stooping); (7) adding new items identified
as being of importance to osteoporosis patients; and (8) re-
moving items considered irrelevant to osteoporosis patients.
All modifications were tracked in an item-tracking matrix.
The change in response option format was introduced
because some participants found it difficult to determine
how best to respond when the recall period was limited to
7 days and the options were limited to the two sets of re-
sponses that were used in the interim version of OPAQ. As a
result of this feedback, later interviews discussed the possibil-
ity of moving from a frequency response set to a severity-
focused response set. Participants generally felt that a severity
response format would be more appropriate.
Following completion of the first-stage cognitive debriefing
interviews, the research team decided to focus the content of
OPAQ-PF on physical function as a measure of the impact of
osteoporosis, concentrating on the domains of mobility (walk-
ing, carrying, and climbing), physical positions (bending,
reaching, picking up, standing, and sitting), and transfers (get-
ting in and out of bed, chairs, and vehicles, and on and off the
toilet). This led to the removal of items addressing fear of
falling, independence, and symptoms. As a result, the instru-
ment generated at the end of the first stage of phase 2 had 16
items in three domains (mobility, physical positions, and trans-
fers) and included a five-point scale that was used throughout
the questionnaire: ‘no difficulty’; ‘a little difficulty’; ‘some
difficulty’; ‘a lot of difficulty’; and ‘severe difficulty’. This
instrument was used in the second stage of phase 2.
Second stage: patient demographics
Demographic data for the 18 participants (eight in diversity
group 1, five in group 2, and five in group 3) recruited for this
stage of the study are shown in Table 1. As in the first stage, this
cohort was predominantly white (83%), with a mean (±SD) age
of 70.0±9.2 years and a mean disease duration of 6.0±4.1 years.
Twelve of the 18 patients had sustained a total of 16 fractures.
The predominant fracture site in this cohort was the hip (n=5).
The remaining fractures were distributed among spine (n=3),
wrist (n=1), ankle (n=1), distal forearm (n=1), humerus
(n=2), ribs (n=1), pelvis (n=1), and foot/toe (n=1). Comorbid
conditions included osteoarthritis, inflammatory arthritis, rheu-
matoid arthritis, diabetes, hypercholesterolemia, asthma, chronic
obstructive pulmonary disease, hypertension, and restless legs
syndrome.
Second stage: concept elicitation
In the second stage of phase 2, saturation was achieved after
the 13th concept elicitation interview. Concept elicitation data
supporting the final version of OPAQ-PF are summarized in
Table 2. First- and second-stage interview data are presented
together. The results demonstrate widespread support for all
items in the domains of mobility, physical positions, and
transfers.
Second stage: cognitive debriefing
Cognitive debriefing results obtained in the first stage of phase
2 reflect participants’ thoughts regarding the design of the
Table 1 Participant characteristics, phase 2 (qualitative research)
Characteristic First stage (n=14) Second stage (n=18)
Age (years; mean±SD) 68.0±11.3 70.0±9.2
Ethnicity (n [%])
White 12 (85.7) 15 (83.3)
Black/African American 1 (7.1) 0
Asian 1 (7.1) 0
Hispanic/Latino 0 1 (5.6)
Middle Eastern 0 1 (5.6)
Mixed 0 1 (5.6)
Main activity (n [%])
Employed full time 2 (14.3) 4 (22.2)
Employed part time 0 2 (11.1)
Self-employed 1 (7.1) 0
Looking after home 4 (28.6) 2 (11.1)
Retired 5 (35.7) 8 (44.4)




Diversity group (n [%])
Group 1 7 (50.0) 8 (44.4)
Group 2 4 (28.6) 5 (27.8)




−2.2 (−3.3 to −0.7) −2.3 (−3.1 to −1.1)
Femoral neck
(median [range])
−2.5 (−3.8 to −0.7) −2.6 (−3.3 to −1.0)
Lumbar spine
(median [range])
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Table 2 Support for OPAQ-PF from concept elicitation data
Domain/item no. Item wording Support from concept elicitation data
Mobility Relevant to all mobility domain items:
1. Walking to do your daily chores or errands (e.g., grocery
shopping, taking out garbage, housework, going to post
office, walking the dog)?
2. Walking unaided so you can do your day-to-day activities?
3. Carrying objects in order to perform your day-to-day
activities (e.g., a bag of groceries, a bag of garbage)?
4. Walking one block?
5. Climbing one flight of stairs or steps?
- Household activities and walking identified as a cause of pain.
- Pain reported as affecting usual activities inside and outside
the home.
- Fractures as a result of osteoporosis can affect the ability to
walk unaided and to complete daily activities unaided.
Participants reported being unable to complete/needing help
completing basic activities and self-care activities, even after
the fracture had healed.
- Large number of mobility problems reported, including
needing to walk with a cane, walking more slowly.
Particularly relevant after a fracture.
- 16 of the 32 analyzed participants reported problems walking.
- Avoiding or limiting the time spent walking as a result of pain.
3. Carrying objects in order to perform your day-to-day
activities (e.g., a bag of groceries, a bag of garbage)?
- Reported losing balance when getting things out of a closet
or carrying things.
- A few participants reported being given a weight restriction
by their doctors.
- Avoiding or limiting the time spent on carrying objects as a
result of pain.
5. Climbing one flight of stairs or steps? - Managing stairs a lot more difficult because of a combination
of not being able to walk quickly, being off-balance, and/or
feeling weak.
Physical positions Relevant to all physical positions domain items:
6. Bending or stooping to do your daily chores or errands
(e.g., grocery shopping, taking out garbage, housework,
going to post office, walking the dog)?
7. Lifting objects in order to perform your day-to-day
activities (e.g., a bag of groceries, a bag of garbage)?
8. Reaching overhead in order to perform your day-to-day
activities?
9. Picking things up from the floor?
10. Standing as much as you needed to in order to perform
your day-to-day activities?
11. Sitting as much as you needed to in order to perform
your day-to-day activities?
- Extending/stretching/leaning forward identified as a cause of
pain.
- Pain reported as affecting usual activities inside and outside
the home.
Fractures as a result of osteoporosis can affect the ability to
walk unaided and to complete daily activities unaided.
Participants reported being unable to complete/needing help
completingbasic activities and self-care activities, even after
the fracture had healed.
6. Bending or stooping to do your daily chores or errands
(e.g., grocery shopping, taking out garbage, housework,
going to post office, walking the dog)?
- 7 of the 32 analyzed participants reported problems bending
down towards the floor.
7. Lifting objects in order to perform your day-to-day
activities (e.g., a bag of groceries, a bag of garbage)?
- 9 of the 32 analyzed participants reported problems lifting.
- Ability to lift sometimes limited as a result of lack of strength
or fear of injury.
8. Reaching overhead in order to perform your day-to-day activities? - 6 of the 32 analyzed participants reported problems reaching.
9. Picking things up from the floor? - 7 of the 32 analyzed participants reported problems bending
down towards the floor.
10. Standing as much as you needed to in order to perform
your day-to-day activities?
- Stiffness occurring if the patient is in one position for too long.
- Avoiding or limiting the time spent standing as a result of pain.
11. Sitting as much as you needed to in order to perform your
day-to-day activities?
- Sitting for too long identified as a cause of pain.
- 8 of the 32 analyzed participants reported problems sitting.
- Avoiding or limiting the time spent sitting as a result of pain.
- Stiffness occurring if the patient is in one position for too long.
Transfers Relevant to all transfers domain items:
12. Getting in or out of bed?
13. Getting in or out of a chair?
14. Getting on or off the toilet?
15. Getting in or out of cars on your own?
- Pain reported as affecting usual activities inside and outside
the home.
- Fractures as a result of osteoporosis can affect the ability
to walk unaided and to complete daily activities unaided.
Participants reported being unable to complete/needing
help completing basic activities and self-care activities,
even after the fracture had healed.
- 11 of the 32 analyzed participants reported problems
getting up.
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questionnaire, the language used, its applicability, the ease
with which the instructions could be interpreted, response
options, and the recall period. The questionnaire underwent
further iterative modifications during the second stage of
phase 2 as a result of participants’ feedback. These modifi-
cations included removing one item, re-wording of items,
and the addition of examples for clarification. As in the first
stage of phase 2, all modifications were tracked in an item-
tracking matrix.
Participants in the cognitive debriefing interviews thought
the length of the questionnaire was good. However, the
overall response to the questionnaire was mixed, some par-
ticipants rating it as very good and others expressing con-
cerns. Examples of concerns included: questionnaire not
sufficiently ‘in-depth’; some aspects of questionnaire being
ambiguous; some items appearing at first glance to ask the
same thing. In general, however, the cognitive debriefing
results showed that the modifications made to the interim
version of OPAQ during the first stage of phase 2 represented
an improvement. The change to a severity format was gen-
erally preferred and items in the ‘mobility’ and ‘physical
positions’ domains performed well following modification
during the course of the interviews. However, items in the
‘transfers’ domain attracted some criticism from patients,
several participants expressing concerns about the relevance
of some items for all osteoporosis patients (e.g., getting in
and out of bed). One participant commented that there should
be an ‘unable to do’ response option and several participants
commented during the concept elicitation interviews that they
avoided certain activities. As a result, the response option
‘completely avoided doing this’ was added to the instrument.
The final changes made to the OPAQ resulted in an instru-
ment with 15 items in three domains (mobility, physical posi-
tions, and transfers), and a single six-point response scale for
each item (‘no difficulty’; ‘a little difficulty’; ‘some difficulty’;
‘moderate difficulty’; ‘severe difficulty’; and ‘completely
avoided doing this’) (Table 3).
Discussion
This report summarizes the two-phase, iterative process by
which OPAQ v.2.0 was modified into a short questionnaire
(OPAQ-PF) focusing specifically on the impacts of osteopo-
rosis on physical function. Although health-related quality of
life (HRQoL) has traditionally been measured in intervention-
al research for osteoporosis to evaluate health status and
economic value, this new instrument represents a useful ad-
vance in osteoporosis research as clinicians and researchers
now have a concise tool that focuses exclusively on mobility,
physical conditions, and transfers in individuals with osteo-
porosis both before and after a fracture event. The measure-
ment of HRQoL provides important information on the health
impact of osteoporosis including subcomponents of physical
functioning; however, HRQoL and the dimension of physical
functioning are by themselves complex, multi-domain con-
cepts. Generic and/or disease-targeted instruments commonly
used in osteoporosis research include the EuroQoL instrument
(EQ-5D), SF-36® Health Survey, or Health Utilities Index
(HUI), andQuality-of-LifeQuestionnaire of the European Foun-
dation for Osteoporosis (QUALEFFO), OPAQ, or Osteoporosis
Quality-of-Life Questionnaire (OQLQ), respectively [23]. These
instruments would most likely not substantiate claims of treat-
ment benefit for medical product labeling as theymay be viewed
by regulatory bodies as not adequate for assessing such a broad
concept as HRQoL and physical functioning [17].
FDA guidance states that qualitative techniques may be
used to develop and validate a modification of an existing
PRO instrument if the modifications involve deletion of por-
tions of the questionnaire or changes to the target patient
population, patient instructions, order of items, item wording,
response options, or recall period [17]. The methodology used
in this study to confirm the adequacy of OPAQ-PF is consis-
tent with these recommendations, and with those of the
ISPOR task force papers [17–19], thereby providing more
reliable evidence of the ability of the instrument to substanti-
ate claims of treatment benefit for the specific concept of
ability to perform daily activities of physical function.
Table 3 Osteoporosis Assessment Questionnaire-Physical Function
(OPAQ-PF)
Mobility
Walking to do daily chores or errands
Walking unaided so day-to-day activities can be carried out
Carrying objects in order to perform day-to-day activities
Walking one block
Climbing one flight of stairs or steps
Physical positions
Bending or stooping to do daily chores or errands
Lifting objects in order to perform day-to-day activities
Reaching overhead in order to perform day-to-day activities
Picking things up from the floor
Standing as much as needed in order to perform day-to-day activities
Sitting as much as needed in order to perform day-to-day activities
Transfers
Getting in or out of bed
Getting in or out of a chair
Getting on or off the toilet
Getting in or out of cars unaided
The questionnaire asked participants to evaluate the impact of osteopo-
rosis on their ability to perform day-to-day activities during the previous
7 days using a 6-point severity response scale: ‘no difficulty’; ‘a little
difficulty’; ‘some difficulty’; ‘moderate difficulty’; ‘severe difficulty’;
‘completely avoided doing this’. The 15 items were presented in three
domains (mobility, physical positions, and transfers) as shown above
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A number of unforeseen problems arose during the first
stage of phase 2; however, the iterative nature of the protocol
allowed us to counter these problems during the second stage.
One issue was the high prevalence of comorbidity, a common
problem in this patient population because osteoporosis typi-
cally affects older adults [2]. Substantial comorbidity preva-
lence made it difficult for many patients to distinguish be-
tween osteoporosis and one of their comorbid conditions as
the cause of symptom experiences. It also caused difficulties
with data interpretation and necessitated discarding informa-
tion regarding symptoms or impacts that the patient could not
specifically relate to osteoporosis. This led to a more focused
attempt to recruit patients without significant comorbidities in
the second stage of phase 2. Papers that describe the creation
of previous versions of OPAQ do not mention a confounding
effect of comorbidity during instrument development [11].
However, Silverman does note that it is routine during analy-
sis of OPAQ data to adjust for a number of factors, including
concomitant medication use, this factor being used as a surro-
gate marker for comorbidity [11]. Likewise, data analyses for
the OPAQ-PF may need to be adjusted for presence of mus-
culoskeletal or other comorbidities (based on clinical exami-
nation or self-report).
Given the focus of previous versions of OPAQ on the
ability to detect change in patient outcomes in association
with fracture, it was expected that fracture and nonfracture
patients would give different responses to the question-
naire. Therefore, we anticipate that the OPAQ-PF will be
able to distinguish between these patient groups, and will
be well placed to capture the decline of osteoporosis pa-
tients as they enter the phase of the disease in which they
experience fractures, and related symptoms and impacts. It
is also likely that OPAQ-PF will be able to document
improvements in patient outcomes associated with fracture
healing. This will be further explored through an ongoing
psychometric validation study.
This study was subject to a number of limitations. First,
content validity of the OPAQ-PF was established in a specific
patient population that was exclusively female, predominantly
white, and already receiving therapy for osteoporosis. There-
fore, validity may not necessarily be assumed for all races/
ethnicities, for men, or for untreated individuals. Second,
because postmenopausal osteoporosis is largely asymptomatic
[24], OPAQ-PF, in common with all other osteoporosis-
specific PRO questionnaires, may provide more useful infor-
mation when used in a population with a history of fracture
than when used in a population without such history. More-
over, assessing women soon after a fracture event may be
particularly informative. Recent data collected during the
Fracture Reduction Evaluation of Denosumab in Osteoporosis
Every 6 Months (FREEDOM) study show that, in women
with incident clinical fractures, the largest deterioration in
PROs is observed when patients are assessed <3 months post
fracture [14]. This type of event-prompted assessment may
allow researchers to document any differences in postfracture
recovery between patients who are receiving therapy and
those receiving placebo.
A third limitation of the study is the somewhat historical
nature of the data used in the IRT analysis. The data in
question were generated during the baseline visit of a 3-year
clinical trial (MORE) conducted between 1994 and 1998 [15].
These data were therefore generated approximately 15 years
before the current study was performed, when available ther-
apeutic options were more limited than they are today. Re-
sponses to OPAQ provided by patients enrolled in MORE in
the 1990s may differ from those of a more contemporary
population receiving current treatments for osteoporosis. A
further limitation regarding the IRT analysis relates to the
criteria used to delete items. Rather than use goodness-of-fit
analyses for this purpose (as is commonly done [16]), we
chose to use ICCs and IICs to drive discussion and decisions
pertaining to item elimination. However, subsequent use of
interview data yielded feedback from patients and was useful
in determining whether any relevant concepts were missing
from the instrument.
One final point relates to the number of participants
interviewed in phase 2 of this study. This number (n=32)
might appear to be low, but this is typical of qualitative
research. Moreover, the crucial criterion for achieving an ac-
ceptable value of ‘n’ in this type of research is the demon-
stration of data saturation having been achieved [21]. This was
the case in both the first and second stages of phase 2.
The version of OPAQ that we have developed represents a
useful advance for both researchers and patients. For re-
searchers, a PRO instrument now exists that focuses solely
on the mobility, physical position, and transfer aspects of
physical function in patients with osteoporosis or low bone
mass density. For patients, the small number of items reduces
the burden associated with completion of the instrument com-
pared with others that may be used. The use of IRT and
qualitative concept elicitation, and cognitive debriefing inter-
views, combined with the clinical expertise of two of the
authors (DTG, SS), resulted in the development of a concise
PRO instrument that focuses on the impact of osteoporosis on
physical function before and after a fracture event. Content
validity of the OPAQ-PF has been established in fracture and
nonfracture osteoporosis patients in the USA.We are currently
conducting a psychometric validation study using OPAQ-PF
to evaluate validity (including the ability of the OPAQ-PF to
discriminate between those with fracture vs. those without),
reliability, and sensitivity to change. Additionally, due to the
comorbidities often seen in patients with osteoporosis that are
associated with older age, it may be necessary to adjust for the
presence of musculoskeletal or other related comorbidities
when conducting analyses of OPAQ-PF data. Further research
is needed to confirm the need for statistical adjustments.
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Conclusions
The OPAQ-PF represents a new PRO tool that is uniquely
tailored to the assessment of physical function in osteoporosis
patients. The cohort used to develop the instrument included
patients both with and without a history of fracture, and
content validity was established in this patient group. This
provides evidence that OPAQ-PF has relevance in a combined
fracture/nonfracture population. Once psychometrically vali-
dated in a range of osteoporotic patient populations, OPAQ-
PF will offer researchers a valid, reliable, and sensitive instru-
ment that will be useful in clinical trials to evaluate pharma-
cological therapies that aim to reduce fracture risk and pro-
mote bone formation following fracture.
Acknowledgments This study was funded by Eli Lilly and Company.
The authors would like to thank Alexis French, Emuella Flood, Nuz
Quadri, and Katie Breheny (Oxford Outcomes, an ICON PLC company,
UK) for their help with the qualitative research design, conduct, and
analysis.
The authors would like to acknowledge Janet Douglas and Jan
McKendrick (Rx Communications, Mold, UK) for medical writing as-
sistance with the preparation of this article, funded by Eli Lilly and
Company.
Conflicts of interest April N. Naegeli and Russel Burge are full-time
employees of Eli Lilly and Company and shareholders of Eli Lilly and
Company stock. Annabel Nixon works for Oxford Outcomes, an inde-
pendent health research company owned by ICON plc. Eli Lilly and
Company funded Oxford Outcomes to conduct the qualitative research
documented in the manuscript on their behalf. Deborah T. Gold is a
consultant for Amgen and Eli Lilly and Company. She receives grant
funding fromNovartis. Stuart Silverman is a speaker for Amgen, Eli Lilly
and Company, Novartis, and Pfizer/Wyeth. He is a consultant for Amgen,
Genentech, Eli Lilly and Company, Novartis, and Pfizer/Wyeth. He
receives research support from Eli Lilly and Company and Pfizer/
Wyeth. He is an employee of Cedars-Sinai Medical Center.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium, pro-
vided the original author(s) and the source are credited.
References
1. National Osteoporosis Foundation (2010) Clinician’s Guide to
Prevention and Treatment of Osteoporosis. National Osteoporosis
Foundation, Washington, DC
2. National Osteoporosis Foundation (2012) Bone health basics: Get the
facts. National Osteoporosis Foundation. http://www.nof.org/node/40.
Accessed 6 December 2012
3. Lau E, Ong K, Kurtz S, Schmier J, Edidin A (2008) Mortality
following the diagnosis of a vertebral compression fracture in the
Medicare population. J Bone Joint Surg Am 90:1479–1486
4. Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK,
Cummings SR (1999)Vertebral fractures andmortality in older women:
a prospective study. Study of Osteoporotic Fractures Research Group.
Arch Intern Med 159:1215–1220
5. Johnell O (1996) Advances in osteoporosis: better identification of risk
factors can reduce morbidity and mortality. J Intern Med 239:299–304
6. Silverman SL (2005) Quality-of-life issues in osteoporosis. Curr
Rheumatol Rep 7:39–45
7. Gold DT, Solimeo S (2006) Osteoporosis and depression: an histor-
ical perspective. Curr Osteoporos Rep 4:134–139
8. Lips P, van Schoor NM (2005) Quality of life in patients with
osteoporosis. Osteoporos Int 16:447–455
9. Silverman SL, Piziak VK, Chen P,Misurski DA,Wagman RB (2005)
Relationship of health related quality of life to prevalent and new or
worsening back pain in postmenopausal women with osteoporosis. J
Rheumatol 32:2405–2409
10. Oglesby AK,Minshall ME, ShenW,Xie S, Silverman SL (2003) The
impact of incident vertebral and non-vertebral fragility fractures on
health-related quality of life in established postmenopausal osteopo-
rosis: results from the teriparatide randomized, placebo-controlled
trial in postmenopausal women. J Rheumatol 30:1579–1583
11. Silverman SL (2000) The Osteoporosis Assessment Questionnaire
(OPAQ): a reliable and valid disease-targeted measure of health-
related quality of life (HRQOL) in osteoporosis. Qual Life Res
9:767–774
12. Silverman SL, Minshall ME, Shen W, Harper KD, Xie S, Health-
Related Quality of Life Subgroup of the Multiple Outcomes of
Raloxifene Evaluation Study (2001) The relationship of health-
related quality of life to prevalent and incident vertebral fractures in
postmenopausal women with osteoporosis: results from the Multiple
Outcomes of Raloxifene Evaluation Study. Arthritis Rheum
44:2611–2619
13. Tosteson AN, Do TP, Wade SW, Anthony MS, Downs RW (2010)
Persistence and switching patterns among women with varied osteo-
porosis medication histories: 12-month results from POSSIBLE US.
Osteoporos Int 21:1769–1780
14. Silverman S, Viswanathan HN, Yang YC, Wang A, Boonen S, Ragi-
Eis S, Fardellone P, Gilchrist N, Lips P, Nevitt M, Palacios Gil-
Antuñano S, Pavelka K, Revicki D, Simon J, Macarios D, Siris ES
(2012) Impact of clinical fractures on health-related quality of life is
dependent on time of assessment since fracture: results from the
FREEDOM trial. Osteoporos Int 23:1361–1369
15. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley
JA, Norton L, Nickelsen T, Bjarnason NH,MorrowM, LippmanME,
Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of
raloxifene on risk of breast cancer in postmenopausal women: results
from the MORE randomized trial. Multiple outcomes of raloxifene
evaluation. JAMA 281:2189–2197
16. Edelen MO, Reeve BB (2007) Applying item response theory (IRT)
modeling to questionnaire development, evaluation, and refinement.
Qual Life Res 16(Suppl 1):5–18
17. Food and Drug Administration (2009) Guidance for Industry.
Patient-Reported Outcome Measures: Use in Medical Product
Development to Support Labeling Claims. U.S. Department of
Health and Human Services; Food and Drug Administration;
Center for Drug Evaluation and Research (CDER); Center for
Biologics Evaluation and Research (CBER); Center for Devices
and Radiological Health (CDRH). http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM193282.pdf. Accessed 6 November 2012
18. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen
E, Ring L (2011) Content validity—establishing and reporting the
evidence in newly developed patient-reported outcomes (PRO) in-
struments for medical product evaluation: ISPOR PRO good research
practices task force report: part 1—eliciting concepts for a new PRO
instrument. Value Health 14:967–977
19. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen
E, Ring L (2011) Content validity—establishing and reporting the
evidence in newly developed patient-reported outcomes (PRO) instru-
ments for medical product evaluation: ISPOR PRO Good Research
Osteoporos Int (2014) 25:579–588 587
Practices Task Force report: part 2—assessing respondent understand-
ing. Value Health 14:978–988
20. Joffe H, Yardley L (2004) Content and thematic analysis. In: Marks D,
Yardley L (eds) Research methods for clinical and health psychology.
Sage, London, pp 56–68
21. Kerr C, Nixon A, Wild D (2010) Assessing and demonstrating data
saturation in qualitative inquiry supporting patient-reported outcomes
research. Expert Rev Pharmacoecon Outcomes Res 10:269–281
22. Willis GB (2005) Cognitive interviewing: a tool for improving ques-
tionnaire design. Sage, Thousand Oaks
23. Tosteson AN, Hammond CS (2002) Quality-of-life assessment
in osteoporosis: health-status and preference-based measures.
Pharmacoeconomics 20:289–303
24. Lewiecki EM (2009) Current and emerging pharmacologic therapies
for the management of postmenopausal osteoporosis. J Womens
Health (Larchmt) 18:1615–1626
588 Osteoporos Int (2014) 25:579–588
